These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 22292365)

  • 1. [Comparative study on four kinds of assessment methods of post-marketing safety of Danhong injection].
    Li X; Tang J; Meng F; Li C; Xie Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2786-8. PubMed ID: 22292365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Study on 10 409 cases of post-marketing safety Danhong injection centralized monitoring of hospital].
    Li X; Tang J; Meng F; Li C; Xie Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2783-5. PubMed ID: 22292364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Necessity of applying pharmacovigilance in post-marketing safety monitoring of traditional Chinese medicine injections].
    Wang HN; Chen W; Fu Z; Du WM; He J
    Zhongguo Zhong Yao Za Zhi; 2008 Mar; 33(5):612-4. PubMed ID: 18536393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Explore method about post-marketing safety re-evaluation of Chinese patent medicines based on HIS database in real world].
    Yang W; Xie Y; Zhuang Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2779-82. PubMed ID: 22292363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Study on method on post-marketing traditonal Chinese medicine safety assessment].
    Kou Q; Zhao S; Feng G; Xie Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2771-5. PubMed ID: 22292361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Analysis of clinical use of Danhong injection based on hospital information system].
    Chen Q; Yi D; Xie Y; Yang W; Yang W; Zhuang Y; Du J
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2817-20. PubMed ID: 22292374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Phase 0 clinical trials and post-marketed re-evaluation of clinical safety in injection of traditional Chinese medicine].
    Wei X; Zhang Z; Xie Y; Wang Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2874-6. PubMed ID: 22292389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Post-marketed re-evaluation of fleabane injection and Dengzhan Shengmai capsule study on treatment in patients with ischemic stroke].
    Wei X; Ye X; Xie Y; Zou Y; Zhao X; Han J; Wang X; Ma Y; Bi Q; Xie Q; Zhao J; Cao X; Chen H; Wang S; Yan R; Han Z; Yi D; Wang Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2789-92. PubMed ID: 22292366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A discussion of key issues on postmarketing reevaluation of Chinese medicine].
    Xie Y; Tian F
    Zhongguo Zhong Yao Za Zhi; 2010 Jun; 35(11):1494-7. PubMed ID: 20822029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Establishment of model of traditional Chinese medicine injections post-marketing safety monitoring].
    Guo XE; Zhao YB; Xie YM; Zhao LC; Li YF; Hao Z
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2974-8. PubMed ID: 24471314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ["Re-evaluation upon suspected event" is an approach for post-marketing clinical study: lessons from adverse drug events related to Bupleuri Radix preparations].
    Wu SX; Sun HF; Yang XH; Long HZ; Ye ZG; Ji SL; Zhang L
    Zhongguo Zhong Yao Za Zhi; 2014 Aug; 39(15):2983-8. PubMed ID: 25423845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Post-marketing re-evaluation of Kudiezi injection study on early treatment in patients with ischemic stroke].
    Ye X; Wei X; Xie Y; Zou Y; Zhao X; Han J; Wang X; Ma Y; Bi Q; Xie Q; Zhao J; Cao X; Chen H; Wang S; Yan R; Han Z; Yi D; Wang Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2793-5. PubMed ID: 22292367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Exploration of how to formulate guidelines on post-marketing traditional Chinese medicine surveillance].
    Zhang W; Xie YM; Yu WY
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2943-8. PubMed ID: 24471309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Security revaluation study based on nested case-control method of Danhong injection].
    Li CX; Tang JF; Meng F; Li XL
    Zhongguo Zhong Yao Za Zhi; 2012 Sep; 37(18):2735-8. PubMed ID: 23285922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Thought on several problems of post-marketing herbs clinical evaluation in special populations].
    Zhou A; Lian F
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2776-8. PubMed ID: 22292362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Thinking on risk assessment and risk management of post-marketing Chinese medicine].
    Yu X; Xie Y; Wang Y
    Zhongguo Zhong Yao Za Zhi; 2012 Jan; 37(2):262-4. PubMed ID: 22737865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Influencing factor and mechanism analysis of adverse drug reaction in traditional Chinese medicine injection].
    Wei X; Xie YM
    Zhongguo Zhong Yao Za Zhi; 2012 Sep; 37(18):2748-51. PubMed ID: 23285926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Technical specifications for intensive hospital safety monitoring of post-marketing Chinese medicine (draft version for comments)].
    Xie YM; Liao X; Zhao YB; Li MQ; Zhang YL; Ma R; Xian SX; Liu J; Li SY; Wen ZH; Yang ZQ; Zou JD; Sun HS; He Y; Li XL; Jiang JJ; Wang ZF; Li YY; Wang LX; Chang YP; Yang W; Zhang W
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2919-24. PubMed ID: 24471304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety monitoring of new anti-malarials in immediate post-marketing phase.
    Edwards IR
    Med Trop (Mars); 1998; 58(3 Suppl):93-6. PubMed ID: 10212911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Construction and realization of real world integrated data warehouse from HIS on re-evaluation of post-maketing traditional Chinese medicine].
    Zhuang Y; Xie B; Weng S; Xie Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2883-7. PubMed ID: 22292392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.